Janux Therapeutics, Inc.
Janux Therapeutics, Inc.
Your view on JANX
Overview
What the company does, where it operates, and who runs it.
About Janux Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Alan Campbell
- Headquarters
- 11099 North Torrey Pines Road, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Alan Campbell
- Headquarters
- 11099 North Torrey Pines Road, San Diego, CA, US
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.
In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Janux Therapeutics, Inc. from FRC's valuation model, read against the market price. JANX last traded at $12.39; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Janux Therapeutics, Inc.. Starting points for Janux Therapeutics, Inc.: EPS -$1.58, beta 2.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Janux Therapeutics, Inc.. Janux Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Janux Therapeutics, Inc.. Trailing twelve-month EPS for Janux Therapeutics, Inc. stands at -$1.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$23.00
Median
$30.50
High
$55.00
Average target · 1 new target in the last 3 months, average $23.00
Analyst Ratings
- Strong Buy0
- Buy13
- Hold3
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.53 | -$0.59 | -$1.65 | -$2.57 |
| Low estimate | -$0.78 | -$0.71 | -$1.87 | -$3.05 |
| High estimate | $0.16 | -$0.53 | -$1.09 | -$2.19 |
| No. of analysts | 10 | 6 | 13 | 12 |
| Year-ago EPS | -$0.52 | -$0.39 | -$1.83 | — |
| Growth | -1.9% | -51.2% | +10.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $4.03M | $2.12M | $27.92M | $7.12M |
| Low estimate | $2.63M | $1.68M | $23.89M | $5.75M |
| High estimate | $5.42M | $2.57M | $40.95M | $8.49M |
| No. of analysts | 6 | 4 | 10 | 8 |
| Year-ago revenue | $0.00 | $3.73M | $10.00M | — |
| Growth | — | -43.1% | +179.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Janux Therapeutics, Inc.. Janux Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Janux Therapeutics, Inc. valued side by side against its closest peers. Janux Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Janux Therapeutics, Inc., and how their positions are changing. At a $758.1M market value, institutional positions materially move Janux Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Janux Therapeutics, Inc. executives and directors. Shares of Janux Therapeutics, Inc. have traded between $21.73 and $71.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Janux Therapeutics, Inc.. Coverage tracks Janux Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Janux Therapeutics, Inc.